BD Innovates With Clinical Trial of Wearable Injector Technology
BD’s New Horizon: The Libertas™ Wearable Injector
BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in global medical technology, has made an exciting announcement. The company is pioneering a new clinical trial that focuses on its cutting-edge BD Libertas™ Wearable Injector technology. This innovative device aims to facilitate the subcutaneous delivery of complex biologics, significantly enhancing patient experience.
Significance of the Clinical Trial
This trial marks the first time a pharmaceutical-sponsored clinical study will utilize the BD Libertas™ Wearable Injector. The decision to employ this technology comes on the heels of impressive results from over 50 previous pre-clinical and clinical investigations that BD conducted. Notably, these studies showcased a remarkable acceptance rate with 100% of participants expressing their willingness to use the BD Libertas™ Wearable Injector if prescribed.
Enhancing Patient Care
The combination product clinical trial is a critical step forward in innovation, particularly in the realm of drug-device combinations. One of the primary goals of this investigation is to improve patient flexibility. It aims to potentially transition patients from intravenous therapies, which typically require hospitalization, to more convenient, home-based self-injections.
Quotes from BD Leadership
Patrick Jeukenne, the worldwide president of BD Pharmaceutical Systems, emphasized the company's dedication to improving patient care. He stated, "This trial demonstrates BD's commitment to helping pharmaceutical companies by advancing large-volume injection science. We are focused on making therapies more accessible and patient-friendly by providing efficient options for biologics." He also highlighted BD’s superior testing capabilities developed through its acquisition of ZebraSci, which positions the company as a leader in drug delivery.
Features of the BD Libertas™ Wearable Injector
The BD Libertas™ Wearable Injector is a state-of-the-art, prefilled drug delivery system designed to enable the subcutaneous administration of complex biologics. The market for biologics is anticipated to exceed $670 billion by 2030. For pharmaceutical companies involved in creating these intricate drugs, the BD Libertas™ Wearable Injector presents a versatile, patient-centered solution. Key features include:
- Supports the delivery of high-viscosity biologics (up to 50 centipoise), making it suitable for a variety of subcutaneous therapies.
- Available in configurations of 2 to 5 mL and 5 to 10 mL, providing flexibility for various therapeutic applications.
- Designed as a fully mechanical, patient ready-to-use system, featuring a user-friendly "peel, stick, and click" mechanism that eliminates the need for end-user filling or assembly.
BD’s Commitment to Innovation
BD is committed to ongoing validations of its fill-finish and final assembly processes with numerous Contract Manufacturing Organizations (CMOs). This proactive approach ensures that the company can assist its pharmaceutical partners throughout the entire journey, from development to commercial-scale production.
For a deeper insight into how the BD Libertas™ Wearable Injector is revolutionizing biologic therapy delivery, interested parties are encouraged to visit www.bd.com/libertas.
About BD
As one of the leading global medical technology companies, BD is dedicated to advancing healthcare through innovation in medical discovery, diagnostics, and care delivery. The company supports healthcare professionals on the frontlines by providing cutting-edge technology that improves clinical therapies and healthcare processes. With a talented workforce exceeding 70,000, BD is committed to enhancing the safety and efficiency of health care.
BD is present in virtually every country and partners with global organizations to tackle some of the most pressing healthcare challenges. By closely collaborating with customers, BD strives to improve health outcomes while reducing costs and increasing efficiencies.
Frequently Asked Questions
What is the BD Libertas™ Wearable Injector?
The BD Libertas™ Wearable Injector is an advanced drug delivery system designed for subcutaneous injection of complex biologics.
What are the benefits of this clinical trial?
This clinical trial aims to evaluate the effectiveness of the injector for easier patient use and to potentially ease the transition from hospital-based infusions to self-injections at home.
How does the BD Libertas™ Wearable Injector improve patient experience?
The injector's user-friendly design allows for convenient self-administration, promoting patient independence and comfort.
What makes BD a leader in medical technology?
BD combines advanced technology with extensive experience in the healthcare sector, enabling them to offer innovative solutions and improve healthcare delivery.
Where can I learn more about BD?
Further information about BD’s products, services, and innovations is available on their official website at www.bd.com.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
